Sanofi ADR

Yahoo Finance • 18 hours ago

No deal yet? Trump readies new tariffs on select drugmakers - report

[Senior woman buying medicine at drugstore] Luis Alvarez The Trump administration plans to impose tariffs on pharmaceutical companies that haven't agreed to lower U.S. drug prices, with an announcement expected as soon as Thursday, _Bloom... Full story

Yahoo Finance • 2 days ago

Global Medical Nutrition Market to Reach USD 31.1 Billion by 2035, Driven by Preventive Healthcare Across North America, Europe & Asia-Pacific - Key Players Nestlé, Abbott, Danone & DSM Lead Innovation

Rising chronic diseases, aging population, and personalized nutrition trends accelerate demand for therapeutic nutrition across hospitals, clinics, and home care settings NEWARK, Del., March 31, 2026 /PRNewswire/ -- According to a latest... Full story

Yahoo Finance • 2 days ago

Kidney Cancer Drugs Market to Grow by $2 Billion During 2026-2030: Pfizer, Novartis, Exelixis, Roche, Bristol Myers Squibb Company, and Bayer Lead the Industry

Company Logo Kidney Cancer Drugs MarketKidney Cancer Drugs Market·GlobeNewswire Inc. Dublin, March 31, 2026 (GLOBE NEWSWIRE) -- The "Kidney Cancer Drugs Market Report 2026" has been added to ResearchAndMarkets.com's offering. The globa... Full story

Yahoo Finance • 3 days ago

Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease

Sanofi Winthrop Industrie Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medicine for pati... Full story

Yahoo Finance • 3 days ago

Communiqué de presse : Le Rezurock de Sanofi approuvé dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte

Le Rezurock de Sanofi approuvé dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte Rezurock est maintenant approuvé dans l’UE pour les adultes et les enfants âgés de 12 ans et plus atteints de GvHD chronique, off... Full story

Yahoo Finance • 3 days ago

How Merck's New Cholesterol Buster Will 'Move The Needle' 'By Removing The Needle'

Merck's experimental cholesterol buster easily outperformed a triplet of medications, the Dow Jones component said Monday. Continue Reading... Full story

Yahoo Finance • 4 days ago

Cutaneous Squamous Cell Carcinoma (cSCC) Market Rises to $8.33 Billion in 2026: Roche, Merck & Co., and Sanofi Leads the Industry

Company Logo Key opportunities include non-surgical treatments, outpatient procedures, and global expansion, particularly in Asia-Pacific. Major players are focusing on immuno-oncology advancements. Cutaneous Squamous Cell Carcinoma (cSC... Full story

Yahoo Finance • 4 days ago

Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline

Company Logo The market offers key opportunities through the growth of personalized therapies, adoption of monoclonal antibodies, digital health integration, and innovative solutions like irinotecan liposome injections. Rising incidence a... Full story

Yahoo Finance • 4 days ago

Recurrent Head and Neck Cancer Squamous Cell Carcinoma Markets and Competition Outlook 2026-2030: Personalized Medicine Drives Revenue Growth, Reaching $4.61 Billion by 2030

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights on market size, reg... Full story

Yahoo Finance • 4 days ago

Cancer Cachexia Market Outlook Report 2026-2030: Personalized Treatments and Digital Tools Elevate Cancer Cachexia Care; Total Revenue to Grow by $600 Million

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Cancer Cachexia Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides critical insights, including market size statistics, regional shares, competiti... Full story

Yahoo Finance • 5 days ago

Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session

AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed either Q4W or Q12W, showed progressivel... Full story

Yahoo Finance • 5 days ago

Communiqué de presse : AAD : Sanofi présente de nouveaux résultats de phase 3 pour l'amlitelimab dans la dermatite atopique lors d'une session de dernière minute

AAD : Sanofi présente de nouveaux résultats de phase 3 pour l'amlitelimab dans la dermatite atopique lors d'une session de dernière minute Dans les études de phase 3 COAST 1, COAST 2 et SHORE, l’amlitelimab, administré 1x/4 sem. ou 1x/12... Full story

Yahoo Finance • 6 days ago

AstraZeneca Shares Rise After Lung Drug Hits Goals in Late-Stage Trials

Tozorakimab met the primary goal in two late-stage clinical trials, reducing the rate at which patients’ symptoms worsened, the company said. Continue Reading... Full story

Yahoo Finance • 6 days ago

Bispecific T-Cell Engagers Market Insights Report (2026-2030) Featuring Strategic Analysis of Pfizer, Johnson & Johnson, Roche, AbbVie, Sanofi and Other Key Players

Company Logo Bispecific T-Cell Engagers MarketBispecific T-Cell Engagers Market·GlobeNewswire Inc. Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The "Bispecific T-Cell Engagers Market Report 2026" has been added to ResearchAndMarkets.com's... Full story

Yahoo Finance • 6 days ago

European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading

European equities traded in the US as American depositary receipts were little changed late Friday m PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 6 days ago

Clinical Nutrition for Diabetes Care Market Report 2026-2030 Featuring Profiles of Key Players - Pfizer, Bayer, Sanofi-Aventis, Abbott Labs, Roche and More

Company Logo The rise of diabetes, demand for specialized nutrition, digital monitoring tools, and home-based management are key trends driving market growth Clinical Nutrition for Diabetes Care MarketClinical Nutrition for Diabetes Care... Full story

Yahoo Finance • 9 days ago

Sanofi Autoimmune Pipeline Grows As Market Weighs Valuation And Momentum

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Sanofi has secured global exclusive rights to Kali Therapeutics' t... Full story

Yahoo Finance • 10 days ago

Press release: Availability of the Q1 2026 aide-mémoire

Availability of the Q1 2026 aide-mémoire Paris, France – March 24, 2026. Sanofi announced today the availability of its Q1 2026 aide-mémoire on the "Investors" page of the company's website: First quarter 2026 results (sanofi.com) Prepa... Full story

Yahoo Finance • 10 days ago

Communiqué de presse : Mise en ligne du document «Q1 2026 aide-mémoire »

Mise en ligne du document «Q1 2026 aide-mémoire » Paris, France – 24 mars 2026. Sanofi annonce la mise en ligne de son « Q1 2026 aide-mémoire » sur la page « Investisseurs » de son site internet. Résultats du premier trimestre 2026 (sano... Full story

Yahoo Finance • 10 days ago

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo BP is a chronic, relapsing skin diseas... Full story